India
· Delayed Price · Currency is INR NATCO Pharma Statistics
Total Valuation
NATCO Pharma has a market cap or net worth of INR 279.39 billion. The enterprise value is 264.61 billion.
| Market Cap | 279.39B |
| Enterprise Value | 264.61B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | Aug 23, 2024 |
Share Statistics
NATCO Pharma has 179.11 million shares outstanding. The number of shares has decreased by -1.64% in one year.
| Shares Outstanding | 179.11M |
| Shares Change (YoY) | -1.64% |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | 29.85% |
| Owned by Institutions (%) | 19.35% |
| Float | 80.42M |
Valuation Ratios
The trailing PE ratio is 17.07 and the forward PE ratio is 14.30. NATCO Pharma's PEG ratio is 0.54.
| PE Ratio | 17.07 |
| Forward PE | 14.30 |
| PS Ratio | 6.42 |
| PB Ratio | 4.78 |
| P/FCF Ratio | n/a |
| PEG Ratio | 0.54 |
Enterprise Valuation
| EV / Earnings | 16.17 |
| EV / Sales | 6.08 |
| EV / EBITDA | 12.23 |
| EV / EBIT | 13.44 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 6.34 |
| Debt / EBITDA | 0.17 |
| Debt / FCF | n/a |
| Interest Coverage | 97.47 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 21.85% |
| Revenue Per Employee | 11.02M |
| Profits Per Employee | 4.15M |
| Employee Count | 3,946 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +74.22% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +74.22% |
| 50-Day Moving Average | 1,366.37 |
| 200-Day Moving Average | 1,045.48 |
| Relative Strength Index (RSI) | 67.39 |
| Average Volume (20 Days) | 1,209,234 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NATCO Pharma had revenue of INR 43.49 billion and earned 16.37 billion in profits. Earnings per share was 91.37.
| Revenue | 43.49B |
| Gross Profit | 36.48B |
| Operating Income | 19.69B |
| Pretax Income | 19.77B |
| Net Income | 16.37B |
| EBITDA | 21.63B |
| EBIT | 19.69B |
| Earnings Per Share (EPS) | 91.37 |
Balance Sheet
The company has 18.49 billion in cash and 3.71 billion in debt, giving a net cash position of 14.78 billion or 82.52 per share.
| Cash & Cash Equivalents | 18.49B |
| Total Debt | 3.71B |
| Net Cash | 14.78B |
| Net Cash Per Share | 82.52 |
| Equity (Book Value) | 58.53B |
| Book Value Per Share | 326.67 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 83.89%, with operating and profit margins of 45.27% and 37.63%.
| Gross Margin | 83.89% |
| Operating Margin | 45.27% |
| Pretax Margin | 45.46% |
| Profit Margin | 37.63% |
| EBITDA Margin | 49.74% |
| EBIT Margin | 45.27% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 5.50, which amounts to a dividend yield of 0.35%.
| Dividend Per Share | 5.50 |
| Dividend Yield | 0.35% |
| Dividend Growth (YoY) | -38.89% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | 1.64% |
| Shareholder Yield | 1.99% |
| Earnings Yield | 5.86% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.
| Last Split Date | Nov 26, 2015 |
| Split Type | Forward |
| Split Ratio | 5 |